首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   352篇
  免费   7篇
林业   5篇
农学   1篇
基础科学   1篇
  23篇
综合类   57篇
农作物   9篇
水产渔业   17篇
畜牧兽医   242篇
园艺   2篇
植物保护   2篇
  2016年   3篇
  2015年   3篇
  2014年   5篇
  2013年   10篇
  2012年   8篇
  2011年   6篇
  2010年   7篇
  2009年   8篇
  2008年   6篇
  2007年   4篇
  2006年   6篇
  2005年   3篇
  2004年   12篇
  2003年   12篇
  2002年   6篇
  2001年   6篇
  2000年   14篇
  1999年   15篇
  1998年   17篇
  1997年   17篇
  1996年   13篇
  1995年   7篇
  1994年   12篇
  1993年   10篇
  1992年   9篇
  1991年   4篇
  1990年   7篇
  1989年   10篇
  1988年   5篇
  1987年   4篇
  1986年   10篇
  1985年   4篇
  1984年   6篇
  1982年   3篇
  1981年   7篇
  1980年   3篇
  1978年   5篇
  1976年   3篇
  1975年   4篇
  1974年   3篇
  1973年   3篇
  1970年   5篇
  1969年   5篇
  1965年   2篇
  1925年   2篇
  1921年   2篇
  1908年   2篇
  1899年   2篇
  1897年   2篇
  1896年   3篇
排序方式: 共有359条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
The relative virulence for chickens of five strains of Pasteurella multocida was evaluated. Twenty groups, each of ten chickens, were inoculated with a standard dose of 10(5) of each of five strains by the intramuscular (I.m.), intravenous (I.v.), intratracheal (I.tr.) or conjunctival (Co) routes. The highest mortality occurred in the groups dosed I.m. and I.v., followed by I.tr. inoculation. The relative virulence of each strain did not change when inoculated by the different routes. The most virulent strain, VP161, caused 100% mortality by all except the Co route. The least virulent strain, VP17, caused a single mortality by the I.v. route, but gave a high level of protection to birds inoculated by both the I.m. and I.v. routes, when challenged by intramuscular injection with (VP161). There was no protection against I.m. challenge in the birds inoculated by the I.tr. or Co routes. Serum antibody levels measured by ELISA correlated with the level of protection against virulent challenge for groups inoculated I.m. or I.v., but not I.tr. Western blots of pooled sera from each group did not show any specific antigen recognition that might explain the observed differences in protection. Inoculation with strain VP17, (both I.m. and I.tr.) also gave a high level of protection to birds challenged with strain VP161 by intratracheal instillation.  相似文献   
15.
A total of 36 tonsil swab samples were collected from healthy swine prior to slaughter at the abattoirs in Can tho and Tien giang provinces of Southern Vietnam. The presence of Pasteurella multocida in these samples was detected by the combination of direct cultivation and isolation, mouse inoculation and the polymerase chain reaction (PM-PCR). P. multocida was detected in 16 samples by PCR, with 17 strains ultimately isolated. All samples were negative for serogroup B by HSB-PCR and conventional serotyping, with isolates identified as A:3, D:1 or D:3. In addition, all samples were determined to be negative for the P. multocida toxin (PMT). Characterisation of isolated P. multocida by REP-PCR and biotyping revealed nine distinct REP profiles and seven biotypes among the 17 isolates. Some correlation was seen with P. multocida isolated from a previous Australian outbreak of acute swine pasteurellosis, and those isolated from fowl cholera outbreaks in Vietnamese poultry.  相似文献   
16.
Experimental mastitis was induced in cows by intramammary infusion of endotoxin, Staphylococcus aureus or Streptococcus agalactiae. The inflammatory response was monitored by somatic cell counting and N-acetyl-beta-D-glucosaminidase (NAGase). NAGase activity was analysed in fresh milk samples in parallel with samples treated by a cycle of freezing and thawing combined with detergent treatment to release the cell-bound NAGase. Before the udder reacted by inflammation, the total NAGase activity consisted of free extracellular activity. Later on when the inflammation was established, much of the milk NAGase remained sequestered intracellularly. S agalactiae was linked with a high degree of cellular NAGase sequestration indicating a blockage of the lysosomal release function from the phagocytes. S aureus delayed the inflammatory response.  相似文献   
17.
Objective To determine the regional incidence and effectiveness of treatment of failure of passive transfer (FPT) in foals. Design A study of disease incidence. Animals Eighty-eight foals and 57 mares from four studs in the practice area of the Rural Veterinary Centre were tested. Procedure Foals were tested for their serum IgG and total serum protein (TSP) concentration within the first 72 hours of life. Colostrum was collected from mares and specific gravity determined. FPT and partial failure of passive transfer (PFPT) of immunoglobulins was diagnosed when serum IgG concentrations were < 4 g/L and 4 to 8 g/L respectively. Owners of foals diagnosed with FPT were offered treatment with 1 to 2 L plasma (TSP > 70 g/L); 9 (64%) of the affected foals were treated. Results Fourteen foals (16%) had FPT whereas 15 (17%) had PFPT. There were significant differences between the mean TSP concentration in foals with FPT (42.6 ± 4.2 g/L), PFPT (48.1 ± 3.9 g/L) and those acquiring adequate passive immunity (58.9 ± 5.5 g/L) (P < 0.01). Sixteen (29%) mares had pre-suck colostral specific gravity < 1.060 and 12 (71%) foals raised by these mares had FPT or PFPT. The incidence of severe disease (categorised by a sepsis score > 11, positive culture of bacteria from blood or disease requiring hospitalisation) in all foals in the first 2 months of life was 10%. However, none of the nine foals with FPT that received plasma experienced severe disease. In contrast, foals with PFPT had an increased susceptibility to severe disease (P < 0.001) when compared with normal foals. Conclusion Treatment of foals with FPT may reduce the subsequent incidence of severe disease. Pre-suck colostral specific gravity and foal TSP may be used to predict the likelihood of FPT and PFPT. Even though the number of foals studied is small the results highlight the importance of optimal management practices in reducing the incidence of FPT and disease associated with this process.  相似文献   
18.
Some of the predisposing factors for the development of degenerative joint disease, such as fatigue, early training, conformation defects, and others, are outlined. Swimming, a controlled weight-bearing exercise, is discussed and strongly recommended for treatment of degenerative joint disease in the horse. A brief review of counterirritants and vesicants, as well as current therapeutic suggestions, are presented. Cryotherapy, which is a relatively new form of counterirritation, is discussed. The benefits and limitations of radiation therapy are briefly discussed, and gamma rays are felt to be superior to x-rays. The most frequently used antiinflammatory drugs are discussed, and the two main categories, corticosteroids and nonsteroidal antiinflammatory drugs, are presented in detail. Among the nonsteroidal antiinflammatory drugs, hyaluronic acid, DMSO, and superoxide dismutase are presented and their mode of action, as well as benefits and disadvantages, are evaluated. Joint lavage is an effective tool in the management of joint disease, because it removes degenerative debris and inflammatory cells from the joint. The management of degenerative joint disease generally involves more than one of the therapeutic regimens mentioned. On the other hand, there is not a single treatment combination that is superior in all situations. The clinician treating degenerative joint disease must select the treatment regimen that works best for him and for the case to be treated. Such a choice must be based on a thorough understanding of applicable therapeutic agents and modes of physical therapy.  相似文献   
19.
20.
Periodontal disease. Etiology and pathogenesis   总被引:1,自引:0,他引:1  
Periodontal disease is the number-one cause of the early loss of teeth in dogs and cats. Some of the factors in the adult animal that play a major role in the development of periodontal diseases are discussed in this article, including overcrowding, malocclusions, diet, developmental defects, and metabolic and systemic disease.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号